2015 Small Molecule Targeted Protein Degradation 
Drug Target Review
OCTOBER 4, 2023
Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. 6 Combining the effect of payloads with different mechanisms of action – an approach that revolutionised small molecule chemotherapy – also holds the promise of enhanced therapeutic activity for ADCs.
The Pharma Data
SEPTEMBER 15, 2020
Our Trilomer® platform of peptidomimetic binders allows for the targeted inhibition of disease-causing proteins, for the treatment of cancer, autoimmune diseases, infectious diseases, and others. “When Amgen first partnered with us in 2015, MBC BioLabs was a single site in San Francisco hosting 40 companies.
Expert insights. Personalized for you.
126 
Let's personalize your content